Dr. Reddy's Laboratories reported a sharp decline in gross margin in its Pharmaceutical Services and Active Ingredients (PSAI) division to 17.2% for fiscal 2026, down from 27.1% the prior year, primarily due to unfavorable product mix and price erosion. The integrated pharmaceutical company operates across global generics, contract services, and proprietary innovations, providing diversified revenue streams but facing cost pressures from inflation and geopolitical factors. Despite these headwinds, ongoing R&D investments and geographic expansion support growth potential, while margin recovery and operational execution remain key near-term monitors. Liquidity remains adequate with a stable current ratio of 1.92 as of March 2025.